Literature DB >> 9163435

Variability in susceptibilities of Haemophilus influenzae to clarithromycin and azithromycin due to medium pH.

A M Nilius1, J M Beyer, R K Flamm, S K Tanaka.   

Abstract

The National Committee for Clinical Laboratory Standards (NCCLS) methods for susceptibility testing of Haemophilus influenzae in Haemophilus test medium allow a pH range of 7.2 to 7.4. However, it is known that bacteria may appear to be less susceptible to macrolides at lower pHs. Forty-four strains of H. influenzae were tested for their susceptibilities to clarithromycin and azithromycin by the disk diffusion and broth microdilution methods. The isolates appeared to be less susceptible at pH 7.2 than at pH 7.4 by both methods. Clarithromycin was less active at pH 7.2 against 43% of the isolates by the disk diffusion method and against 52% of the isolates by the broth microdilution method. Similarly, azithromycin was less active at pH 7.2 against 41 and 45% of the isolates by the disk diffusion and broth microdilution methods, respectively. Forty-two isolates were classified as clarithromycin susceptible and all isolates were classified as azithromycin susceptible by the disk diffusion method, regardless of the medium pH. However, only 21 isolates were clarithromycin susceptible at pH 7.2 and 34 isolates were susceptible at pH 7.4 by the broth microdilution method, even though quality control results indicated valid testing at both pHs. This study indicated that the results of tests of the susceptibility of H. influenzae with clarithromycin and azithromycin are highly dependent on the pH of the medium. Test results and their interpretations varied even when the medium pH was within the NCCLS-approved range and, coupled with the current NCCLS breakpoint of 8 microg/ml in the case of clarithromycin, may explain some of the observed discordances between the disk diffusion and broth microdilution methods.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9163435      PMCID: PMC229740          DOI: 10.1128/jcm.35.6.1311-1315.1997

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  10 in total

Review 1.  In vitro susceptibility testing of Haemophilus influenzae: review of new National Committee for Clinical Laboratory Standards recommendations.

Authors:  G V Doern
Journal:  J Clin Microbiol       Date:  1992-12       Impact factor: 5.948

2.  Reassessment of methods for testing the susceptibility of Haemophilus influenzae to clarithromycin.

Authors:  A L Barry; T S Schultheiss; S D Brown; P C Fuchs
Journal:  J Antimicrob Chemother       Date:  1996-04       Impact factor: 5.790

3.  Effect of adjustment of the pH upon sensitivity of urinary gram-negative bacilli to nine antibiotics.

Authors:  J Klastersky; L Debusscher
Journal:  Int Z Klin Pharmakol Ther Toxikol       Date:  1971-04

4.  Relative potencies of azithromycin, clarithromycin and five other orally administered antibiotics.

Authors:  A L Barry; P C Fuchs; S D Brown
Journal:  J Antimicrob Chemother       Date:  1995-04       Impact factor: 5.790

5.  Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans.

Authors:  D J Hardy; R N Swanson; R A Rode; K Marsh; N L Shipkowitz; J J Clement
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

6.  Erythromycin, clarithromycin, and azithromycin: use of frequency distribution curves, scattergrams, and regression analyses to compare in vitro activities and describe cross-resistance.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

7.  Validation of NCCLS macrolide (azithromycin, clarithromycin, and erythromycin) interpretive criteria for Haemophilus influenzae tested with the Haemophilus test medium. National Committee for Clinical Laboratory Standards.

Authors:  R N Jones; G V Doern; E H Gerlach; J Hindler; M E Erwin
Journal:  Diagn Microbiol Infect Dis       Date:  1994-04       Impact factor: 2.803

8.  Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides.

Authors:  D J Hardy; D M Hensey; J M Beyer; C Vojtko; E J McDonald; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1988-11       Impact factor: 5.191

9.  Enhancing effect on alkalinization of the medium on the activity of erythromycin against gram-negative bacteria.

Authors:  L D Sabath; V Lorian; D Gerstein; P B Loder; M Finland
Journal:  Appl Microbiol       Date:  1968-09

10.  Variability of clarithromycin and erythromycin susceptibility tests with Haemophilus influenzae in four different broth media and correlation with the standard disk diffusion test.

Authors:  A L Barry; P B Fernandes; J H Jorgensen; C Thornsberry; D J Hardy; R N Jones
Journal:  J Clin Microbiol       Date:  1988-11       Impact factor: 5.948

  10 in total
  4 in total

1.  Analysis of MIC and Disk Diffusion Testing Variables for Gepotidacin and Comparator Agents against Select Bacterial Pathogens.

Authors:  L M Koeth; J M DiFranco-Fisher; N E Scangarella-Oman; L A Miller
Journal:  J Clin Microbiol       Date:  2017-03-22       Impact factor: 5.948

2.  Influence of variations in test methods on susceptibility of Haemophilus influenzae to ampicillin, azithromycin, clarithromycin, and telithromycin.

Authors:  P C Fuchs; A L Barry; S D Brown
Journal:  J Clin Microbiol       Date:  2001-01       Impact factor: 5.948

3.  Dynamics of clarithromycin and azithromycin efficacies against experimental Haemophilus influenzae pulmonary infection.

Authors:  J D Alder; P J Ewing; A M Nilius; M Mitten; A Tovcimak; A Oleksijew; K Jarvis; L Paige; S K Tanaka
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

4.  Development of EUCAST zone diameter breakpoints and quality control criteria for ceftazidime-avibactam 10-4 μg.

Authors:  L M Koeth; E Matuschek; G Kahlmeter; G Stone
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-03-30       Impact factor: 3.267

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.